⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14490646 | 1.00 | — | — | |
| SCHEMBL24761183 | 0.86 | APLNR (0.35) | — | |
| SCHEMBL24589003 | 0.78 | — | — | |
| SCHEMBL18236385 | 0.78 | — | — | |
| SCHEMBL25776719 | 0.78 | — | — | |
| SCHEMBL24589002 | 0.78 | — | — | |
| SCHEMBL24588935 | 0.78 | — | — | |
| SCHEMBL24588939 | 0.78 | — | — | |
| SCHEMBL15114886 | 0.78 | — | — | |
| SCHEMBL497813 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3159345-A1 | INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2004083177-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |